Otros idiomas Annexin Pharmaceuticals AB

Acciones

ANNX

SE0009664154

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 15:40:35 14/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,293 ^SEK	-7,28 %		-4,87 %	+12,69 %

30/04	Annexin Pharmaceuticals AB (publ) anuncia el reclutamiento completo del estudio de fase II con señales positivas	CI
25/04	Annexin Pharmaceuticals AB anuncia que el último paciente ha sido tratado con el nuevo fármaco en investigación ANXV en el estudio de fase 2A	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

The subscription period in Annexin Pharmaceuticals’ rights issue begins today	14/05
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	07/05
BioStock: Annexin's phase II study fully recruited with positive signals	30/04
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	30/04
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04
Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	25/04
BioStock: Annexin towards completion of phase II study and share issue	18/04
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03
BioStock: Strong start for Annexin in 2024	14/02
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Update on Annexin´s RVO study confirms promising signals of effect	08/02
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11
Annexin granted additional patent protection in the US	14/11
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Annexin Pharmaceuticals AB

Acciones

ANNX

SE0009664154

Otros idiomas

Filtros